newsfilter
← Latest News
Business Wire·

Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

– MARIO-3 Update in Patients with 1L TNBC showing 52% increase in one-year progression free survival rate in ITT patient population compared to Impassion130 benchmark – – Business development discussions advancing with